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The observations that led to the discovery of 
transfer factor have been the subject of recent 
reviews [1,2] and will receive only brief mention 
here. Soon after Lawrence [3] reported that delayed 
hypersensitivity could be transferred with lymph-
oid cells from reactive human donors to previously 
unresponsive recipients, it became clear that, in 
humans, this phenomenon had several features 
that were different from previous observations in 
guinea pigs. First, in humans the passively 
acquired responsiveness persisted for many 
months even though the donor and recipient were 
genetically disparate. Second, in humans it was 
possible to transfer delayed hypersensitivity with 
nonviable and even disrupted cells [4] . Finally, it 
was shown that the active component in the cell 
lysates was dialyzable [5] and therefore had a low 
molecular weight. Even now, the chemical nature 
and mechanism of action of transfer factor are 
unknown. To some extent progress in this area has 
been hampered by the lack of a suitable in vitro 
assay and an animal model for studying transfer 
factor. 
The studies in our laboratory have been directed 
towards identification of components and activi-
ties in dialysates of leukocyte lysates that could 
modulate immunologic inflammation, isolation of 
the material(s) responsible for passive transfer of 
delayed hypersensitivity in man, determination of 
the specificity of passive transfer with transfer 
factor, and evaluation of the efficacy of reconstitu-
tion of immunologic competence with transfer 
factor in treating patients with cellular immune 
deficiency syndromes. 
PREPARATION OF DIALYZABLE TRANSFER 
FACTOR (TF) 
In our studies TF has been prepared from 
peripheral blood leukocytes collected with a con-
tinuous-flow blood cell separator or a Latham 
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cAMP: 3' ,5' -cyclic adenosine monophosphate 
cGMP: 3' ,5' -cyclic guanosine monophosphate 
H-F: Hypaque-Ficoll cell 
MIF: migration inhibitory factor 
SK-SD: Streptokinase-Streptodornase 
TF: transfer factor 
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Blood Processor. The usual yield from a 3- to 4-hr 
run is 6-12 x 109 leukocytes in 150-250 ml of blood. 
The cells are first washed in phosphate-buffered 
saline to remove anticoagulants and plasma com-
ponents. The protocol for preparing the TF varies 
slightly depending upon the plans for the prepara-
tion. In some cases whole cell suspensions includ-
ing leukocytes, erythrocytes, and platelets are 
disrupted by repeated freezing and thawing. In 
other instances the cells are purified further by 
centrifugation through Hypaque-·Ficoll gradients 
[6] followed by washing with cold Hanks' balanced 
salt solution. The leukocyte suspensions prepared 
by this method contained 60-90 % lymphocytes, 
10-30% monocytes, 0-5 % neutrophils, and 0-3 % 
basophils; all preparations also contained plate-
lets. After disruption by freeze-thawing, the cell 
lysates are dialyzed against distilled water or 0.02 
M NH 4HC0 3 , pH 7.4. The dialysates are then 
concentrated by lyophilization and reconstituted 
to an arbitrary concentration of 3 x 108 lym-
phocyte equivalents per ml. In other experiments 
cell lysates were dialyzed against Medium 199 or 
RPMI 1640 in attempts to confirm the in vitro 
effects of TF on lymphocyte transformation re-
ported by Ascher et al [7]. 
NONIMMUNOLOGIC ACTIVITIES IN DIALYZABLE TF 
Chemotactic activity 
In 1974, it was reported that dialyzable TF 
contained potent chemotactic activity [8]. Accord-
ing to the in vitro assays, the chemotactic factor 
was especially active on neutrophils, but when 
compared with a standard chemotactic stimulus 
(endotoxin-activated serum), the TF had much 
less chemotactic activity for monocytes. Because of 
the temporal limitations of in vitro assays for 
chemotaxis, small volumes of TF or diluent were 
injected intradermally into rhesus monkeys [9]. 
Full-thickness skin biopsies were obtained at 2, 5, 
and 24 hr and examined for the intensity and 
composition of the cellular infiltrates. At 2 hr there 
was a profuse infiltration with neutrophils, but no 
increase in the number of mononuclear leukocytes. 
By 5 hr, there was a significant increase in the 
mononuclear cell infiltrate while the neutrophilic 
infiltrate was essentially unchanged. At 24 hr, the 
neutrophil infiltrate was subsiding; the mononu-
clear infiltrate was still increasing in intensity. The 
stimulus for the late mononuclear cell infiltration 
has not been identified, but two mechanisms are 
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under consideration. First, chemotactic factors 
could be released from the infiltrating neutrophils 
[10]. Second, the infiltrate could be due to a direct, 
but delayed response to a component in the TF. 
Two observations suggest that the chemotactic 
property of TF has biologic significance. In sar-
coidosis it has been reported [11] that anergic 
patients may respond to TF by developing reactive 
skin tests proximal to the sites of injection of TF, 
but that responses to tests with the same antigens 
applied at remote sites remain negative. Moreover, 
in a study of the effects of TF on rejection of skin 
allografts, the most marked enhancement of graft 
rejection was seen when the TF was injected in the 
vicinity of the graft [12]. In both observations, it is 
possible that the chemotactic activity in the TF 
contributed to the inflammatory responses by 
amplifying low-intensity immunologic reactions. 
In this connection, Lawrence and Pappenheimer 
[13] have reported that TF was released into the 
culture fluids when antigen-responsive lympho-
cytes were exposed to the appropriate antigens in 
vitro. If a similar response occurs in vivo at the 
sites of skin tests, infectious organisms, tumors , or 
other depots of antigen, the chemotactic activity in 
the TF could further enhance local inflammatory 
reactions even in normal subjects. 
Effects on Cy clic Nucleotide Accumulation 
It is now well established that cyclic nucleotides 
exert modulating effects on a variety of immuno-
logic and inflammatory responses. In general, in-
creasing cellular cyclic guanosine monophosphate 
(cGMP) enhances responses such as antigen-de-
pendent release of histamine and slow-reacting 
substance of anaphylaxis (SRS-A) [14] , T -cell-
mediated cytotoxicity [15] , release of lysosomal 
enzymes from neutrophils [16], and both random 
and directed movement of neutrophils [17, 18]. In 
most instances, increasing the cellular cyclic aden-
osine monophosphate (cAMP) has the effect of 
depressing these responses [19] . 
The possibility that dialyzable TF might affect 
leukocyte cyclic nucleotides has recently been 
examined [20]. As shown by the data in Table I, 
dialyzable TF prepared from either whole leuko-
cytes (WL) or Hypaque-Ficoll (H-F) purified cells 
caused marked accumulation of cG MP by leuko-
cytes. 
The responding cell population was identified by 
comparing responses in H-F cells that had been 
further purified by incubation on plastic surfaces. 
The plastic-adherent, neutral red-staining mono-
cytes showed marked increases in cG MP while the 
nonadherent, lymphocyte-rich cell fractions were 
essentially unresponsive (Tab. II). Passing suspen-
sions of leukocytes through glass bead columns 
removed most of the monocytes; the cells that were 
not retained on the columns did not respond with 
increases in cGMP. Neutrophils, too, did not show 
increases in cellular cGMP after incubation with 
TF. 
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Plastic-adherent and nonadherent mononuclear 
cells and dextran-purified neutrophils were lysed 
and dialyzed; the dialysates were lyophilized and 
then reconstituted in a manner identical to that 
described previously for TF . The dialysates of all 
three cell lysates markedly stimulated cGMP ac-
cumulation by mononuclear cells. This observation 
prompted a search for substances in dialyzable TF 
that had previously been shown to cause cGMP 
TABLE 1. Effects of dialyzable transfer factor on leukocyte 
cGMP accumulation 
cGMpa 
Preparation (pmol/IO' WBC) 
No . 
Resting Stimulated ~ 
48 H-F b 3.1 16.0 12.9 
51/56 WU 1.4 11 .2 9.8 
34 WL 1.2 8.1 6.9 
40 H -F 2.8 10.3 7.5 
38 H-F 1.4 7.9 6.5 
37 WL 2.8 12.0 9.2 
36 H -F 1.2 6.7 5.5 
Diluent 1.4 1.3 -0.1 
a Transfer factor preparations contained 3 x 108 lym-
phocyte equivalents per ml; 0.4 ml was added to 2.0 ml of 
leukocytes and incubated for 5 min. The reaction was 
stopped with cold perchloric acid, the cGMP was ex-
tracted and assayed with a commercial radioimmuno-
assay. 
b H-F indicates preparations from Hypaque-Ficoll 
purified cells. 
C WL indicates preparations from whole leukocytes. 
T ABLE II. Effec t of dialy zable material from leukocyte 
lysates on cGMP content of plastic-adherent , plastic 
nonadherent, and polymorphonuclear leukocy tes 
Neutral cGMP 
Expt. red (pmols/10 7 cells) positive 
(%) Buffer Dialysate 
Plastic-adherent 
cells 
1 86 1.5 ± 0.4 16 .1 ± 1.0 14.6 
2 86 3. 1 ± 1.7 16.0 ± 1.2 12.9 
3 86 3.5 ± 1.5 20.0 ± 0.9 16.5 
N onadherent 
cells 
1 11 0.4 ± 0.1 2.1 ± 0.2 1.7 
2 20 0.7 ± 0.1 1.4 ± 0.5 0.7 
3 7 2.8 ± 1.1 6.0 ± 1.4 3.2 
Col umn -purified 
cells 
Pre-column 15a 2.1 ± 0.2 11.2 ± 0.4 9.1 
Post-column 2a 2.8 ± 0.3 3.2 ± 0.0 0.4 
N eutrophils 
1 0.9 ± 0.4 0.8 ± 0.2 -0.1 
2 1.5 2.5 ± 0.2 1.0 
a Scored as monocytes on Wright 's stained smears 
rather than neutral red preparations 
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accumulation; it was found that dialyzable TF 
preparations contained both ascorbate and sero-
tonin (Tab. III). 
The crude dialyzable TF was then fractionated 
by filtration through a column of Sephadex G-25 
(Fig. ). Pooled fractions were lyophilized, reconsti-
tuted, and assayed for effects on leukocyte cGMP. 
Activity was found in both Fractions I and II that 
appeared in the region of the [14C ]ascorbate 
marker and were shown by direct assay to contain 
ascorbate. Cyclic GMP-stimulating activity was 
also present in Fractions III and IV, fractions that 
did not contain detectable ascorbate. No cGMP-
stimulating activity was found in the region of the 
[14C ]serotonin marker, probably because the con-
centration of serotonin in the preparations was 
below the threshold of sensitivity of the assay . 
To identify the component in dialysates of lysed 
neutrophils that caused accumulation of cGMP, 
these lysates were passed through the same column 
and identical fractions were assayed for effects on 
cellular cGMP. Only the ascorbate-containing 
fractions were active. 
TABLE III. Ascorbate and serotonin content of dialy zable 
transfer factor 
Preparation Ascorbate 
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FIG. Gel filtration of whole dialyzable transfer factor. 
One ml (3 X 108 lymphocyte equivalents) was applied to 
a 2.5 x 85 cm column of Sephadex G-25. The elution 
profile was monitored at 255 nm. Tubes were pooled into 
fractions which were lyophilized 'and then assayed for 
effects on mononuclear cell cGMP. The elution regions of 
the [14C ]ascorbate and [HC ]serotonin markers are shown . 
(From Kirkpatrick CR, Smith TK: In Transfer Factor. 
Edited by MS Ascher, AA Gottlieb, CR Kirkpatrick. 
New York, Academic, 1976, p 161) 
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TABLE IV. Effect of dialyzable transfer factor of 
mononuclear cell cAMP 
cAMP 
Expt_ (pmols / 107 cells) 
Resti ng Stimulated ~ 
1 71.6 102.0 30.4 
2 67 .6 107 .5 39 .9 
3 56.0 80.0 24.0 
TABLE V. Histam ine content of dialy zable transfer fa ctor 
Preparation Histaminea 
No. ( x lO - 6 M) 
48 1.80 
51 /56 3.06 
34 6.58 
50/75 0.54 
40 7.39 
80 6.40 
72/76 4.50 
a Samples were diluted 1: 10 in Tyrode's solution and 
100 ,ul were added to the bioassay chamber. The original 
transfer factor preparations contained 3 X 10 8 lympho-
cyte equivalents per ml. 
The TF -containing dialysates also produced 
small increases in mononuclear cell cAMP (Tab . 
IV) . The fraction of the TF that causes this 
increase and the identity of the responding cells 
have not been determined . Of possible relevance to 
cAMP accumulation is the finding that all of our 
TF preparations contain histamine (Tab . V), a 
substance known to cause cAMP accumulation in 
leukocytes [21] . 
IMM UN OLOGIC ACTIVITIES IN DIALYZABLE TF 
Effects on Leukocy te Function 
We have previously reported that lymphocytes 
from recipients of TF respond to specific antigens 
in vitro by secreting lymphokines such as macro-
phage migration inhibitory factor (MIF) [22]. In 
contrast, the same lymphocytes did not respond to 
the antigens with enhanced DNA synthesis, sug-
gesting that the primary effects of TF are on cell 
lines or cell interactions that culminate in differen-
tiation of antigen-responsive, lymphokine-produc · 
ing cells. However, the specific site of act ion of TF 
in this phenomenon has not been identified. 
Isolation of An Immunologically Active Fraction 
From Whole Dialyzable TF 
Partial purification of the skin test-converting 
moiety in crude TF has been reported by Zucker-
man and co-workers [23]. Their active fraction was 
obtained by gel filtration through columns of 
Sephadex G-25 and corresponded to our Fraction 
IV (Fig.). We have recently completed a series of 
experiments that confirm their findings. Dialyza-
ble TF from a donor with positiv,e delayed skin 
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responses to PPD, Candida, and Streptokinase-
Streptodornase (SK-SD) and a negative tricho-
phytin test was passed through a 5.0 x 85 cm 
column of Sephadex G-25 in 0.02 M NH 4HC0 3 
buffer. The material corresponding to Fraction IV 
(Fig.) was pooled, lyophilized, and designated Pool 
A. All other fractions from the column were pooled 
together and lyophilized and designated Pool B. 
When the material was reconstituted with sterile 
saline, it was assumed that the active material was 
contained in only one of the two fractions. The 
concentration was adjusted so that the extract 
from 3 x 108 lymphocytes was contained in each 
ml. 
Two anergic patients with chronic mucocutane-
ous candidiasis were given 6 x 108 lymphocyte 
equivalents of Pool A. Both developed positive 
delayed hypersensitivity responses to PPD and 
Candida; one responded to SK-SD. A third patient 
also had negative skin tests to Candida and PPD 
but a positive (1.4 cm) response to SK-SD. This 
patient received 6 x 108 lymphocyte equivalents of 
Pool B; there were no changes in his delayed 
allergic responses. Subsequently, this patient 
received 6 x 108 lymphocyte equivalents of Pool A. 
When skin tested one week later, both the PPD 
and Candida skin tests were positive. 
The composition of this fraction is currently 
under study. As shown in the Figure, it strongly 
absorbs 255 nm ultraviolet light. However, this 
fraction has relatively little absorbance at 280 nm; 
the 255/280 ratio is about 10. Recent experiments 
in our laboratory and by others [24, M. S. O'Do-
risio et aI, personal communication] have estab-
lished that essentially all of the 255 nm absorbance 
is due to hypoxanthine . Preliminary data indicate 
that xanthine oxidase-treated TF is still capable of 
causing conversion of delayed cutaneous hypersen-
sitivity in rhesus monkeys. Thus, it seems probable 
that the hypoxanthine is a product of purine 
catabolism and not an essential component ofTF. 
CLINICAL STUDIES WITH TF 
Our studies of the clinical effects of immunologic 
reconstitution with TF have been limited to 
patients with chronic mucocutaneous candidiasis 
[25]. This disorder, while uncommon, often indi-
cates an abnormality in cell-mediated immunity 
which may be generalized or limited to Candida 
antigens. For example, of the 27 chronic candidia-
sis patients studied at the National Institutes of 
Health, 8 were completely anergic, 10 did not show 
delayed hypersensitivity to Candida, but reacted 
to other antigens such as SK-SD or tetanus toxoid, 
and only 9 had positive Candida skin tests. 
In considering possible immunologic methods for 
treating these patients, two questions were 
addressed. First, was it possible to correct the 
immunologic defects; and, second, would correc-
tion of the defects be accompanied by any clinical 
benefits? The initial approach to the first question 
involved transfusion of large numbers of lympho-
cytes from Candida skin test-positive donors into 2 
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patients. In both instances, negative skin tests 
became positive, and in one case there was marked 
clearing of the mucocutaneous lesions [26]. 
Because transfusions of immunocompetent cells 
carried the potential hazard of graft-versus-host 
reactions, we turned to TF as the reconstituting 
agent. 
To obtain some homogeneity in the patient 
population, only anergic patients with childhood-
onset candidiasis were entered into the study. Six 
patients received monthly injections of TF from a 
Candida-positive donor. The dose was 6 x 108 
lymphocyte equivalents per injection and in each 
case conversion of delayed skin reactions to Can-
dida was obtained. At the end of the 6-month 
study period 4 patients showed no change in their 
clinical status and 2 patients were worse. Thus, 
under the conditions employed in this trial, TF was 
not an efficacious therapeutic agent. 
The study was then changed to include treat-
ment of the patients with amphotericin B to induce 
remissions and to use the TF as a form of con-
solidation therapy. Most of the patients had · 
received amphotericin previously, but had 
relapsed 4 to 6 months after termination of ther-
apy. The total intravenous dose was about 15 mg 
per kg and was given over 8 to 10 weeks. The TF 
(from a Candida-positive donor) was started about 
2 weeks before termination of the course of 
amphotericin. Monthly injections of 6 x 108 lym-
phocyte equivalents were given for 4 months fol-
lowed by 2 bimonthly injections. Most patients 
now receive TF every 4 months. 
Currently, two patients are still in cutaneous 
remissions 4 years after stopping amphotericin B, 
three other patients are in remissions after 3 years, 
1 year, and 8 months, respectively. Thus, this 
schedule has been successful in controlling the 
cutaneous component of the disease. The results 
with mucous membrane candidiasis have been less 
satisfactory. Both of our longest-treated patients 
have mild to moderate oral candidiasis that resists 
local therapy. 
We have just begun a new study in which 
amphotericin Band TF from a donor with a 
negative Candida skin test are being used. 
CONCLUSIONS 
The identity and the mechanism of action of the 
TF molecule(s) have not been determined, 
al though considerable progress has been made in 
purification of the crude material. Also unresolved 
is the issue of the "specificity" of passive transfer 
with TF. It seems clear that in addition to the 
apparent immunologic specificity ofTF, the prepa-
rations also contain nonspecific activities that may 
amplify low-intensity inflammatory responses. In 
one disease, chronic mucocutaneous candidiasis, 
TF is an efficacious agent, but only when used in 
conjunction with antibiotic therapy. 
The cGMP studies were done in collaboration with Drs. 
Jeffrey Sandler and Vincent Manganiello. Drs. Richard 
Sept. 1976 
Clark and Allen Kaplan performed the histamine bioas-
says. 
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DISCUSSION 
Cohen: Mucocutaneous candidiasis is apparently a 
manifestation of infection occurring in several types of 
immunodeficiency disorders rather than a single disease 
entity. Was there some identifiable common denomina-
tor of underlying pathology among the patients in your 
:.;eries? In your experience or in other clinical investiga-
tions with which you may be familiar have there been any 
leads to suggest the characteristic type(s) of immunologic 
observation(s) for which the use of transfer factor (TF) 
might be predictably efficacious or not likely to be 
helpful in the treatment of complicating chronic mucocu-
taneous candidal infection? 
Kirkpatrick: Chronic mucocutaneous candidiasis is 
no more of a specific disease than is anemia. However, it 
is a hallmark that strongly suggests a defect in host 
defenses. Roughly 25 % of our patients are anergic and an 
additional 50% fail to show cellular immunity to Candida 
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antigens . The remainder are normal by the tests that we 
currently use. They may have defects that we do not 
recognize. The examples of treatment failure are hard to 
document because they do not get reported. I do know of 
patients with candidiasis who failed to respond to TF 
alone, just as I described with our own patients. I do not 
know of failures when adequate antibiotic therapy was 
used with TF. 
Austen: Why is moniliasis mucocutaneous if the 
defect is in host cellular immunity, i.e. , why is there not 
more systemic disease? 
Would you expand your discussion of TF chemistry? 
Kirkpatrick: The infection is quite superficial with 
the organisms being present in the stratum corneum. I 
suspect that the high levels of serum antibody may 
prevent dissemination to parenchymal organs. In this 
regard the skin may be a " T-cell domain. " Deficient 
T -cell function permits infection of the skin. Restoration 
of T -cell immunocompetence prevents reinfection. 
There were a number of new points raised at the recent 
Transfer Factor Workshop. First, the column fraction 
that transfers skin reactivity in our hands and in the 
hands of Dr. Tomar and Dr. D'Orisio and co-workers did 
not contain orcinol-reacting material. The high absorb-
ance of 255 or 260 nm light is due to hypoxanthine . 
However, xanthine oxidase-digested TF will still pas-
sively confer delayed hypersensitivity on rhesus mon-
keys. 
This column fraction does contain Lowry-reacting 
material and presumably contains polypeptides . In this 
regard, one should note that Dr. Spitler has reported that 
pronase digestion of TF destroyed the property of skin 
test transfer. Dr. Arthur Gottlieb has a fraction from 
Sephadex G-10 that transfers local skin reactivity. By 
dialysis through a special membrane he has obtained a 
fraction that has a molecular weight of less than 3000 
daltons and causes an early erythematous reaction in the 
skin. A second fraction of larger molecular weight ( > 3000 
daltons) does not give this nonspecific reaction but 
transfers local sensitivity to antigens . Both fractions are 
fluorescamine positive. Finally , Dr. Krohn from Finland 
has a fraction that is chemically similar if not identical to 
uracil. In fact it co-chromatographs with uracil ; when the 
material was scraped off of the thin layer plate and tested 
in vivo, skin test reactivity was transferred. 
Rocklin: It would appear that the Candida-positive 
principle in TF is indeed important for the treatment of 
patients with mucocutaneous candidiasis. Drs. Littman, 
David, and I have observed in one such patient that TF 
prepared from Candida-positive donors induced a pro-
longed remission in the skin disease (approximately 4 to 6 
months) , while material prepared from Candida-negative 
donors had no effect either clinically or immunologically. 
Voorhees: Would you discuss some of the details of 
your cGMP assay? Is cGMP elevated by material from 
freeze-thawed liver cells (as a control) as well as by TF? 
Do you find it necessary to purify your extracts contain-
ing cGMP before radioimmunoassay? 
Kirkpatrick: The cGMP assays are run with a radio-
immunoassay using reagents from Collaborative Re-
search. The reaction is stopped with PCA. Cyclic AMP 
and cGMP are separated on Ag-1-X8 formate columns 
using 2 N formic acid to elute cAMP and 4 N formic acid 
to elute cGMP. The recovery of cGMP is 35 to 40 %. We 
have not examined liver or kidney cell dialysates. I would 
not be suprised if these materials were active simply 
because of their ascorbate content. The columns contain 
Sephadex G-25 in 0.01 N NH4HCO a, pH 7.4. The use of 
this volatile buffer permits concentration of material 
without increasing the salt content. 
